Paper Details

  1. Home
  2. Paper Details

Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections.

Author: BarnettB B, SidwellR W, SmeeD F

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Two anti-murine cytomegalovirus (MCMV) immunotoxins used in combination with ganciclovir (GCV) or cidofovir (HPMPC) showed synergistic inhibition of virus yield in vitro. In MCMV-infected SCID mice, the combination of immunotoxin plus GCV was better than GCV alone, extending survival time.
Paper Details　
Original Abstract of the Article :
The effects of two anti-murine cytomegalovirus (MCMV) immunotoxins used in combination with ganciclovir (GCV) or cidofovir (HPMPC) against MCMV were determined in vitro and in mice. The inhibitors were added to cell cultures 24 or 48 h after MCMV adsorption so as to not affect the initial infection ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0166-3542(95)00986-8

データ提供：米国国立医学図書館（NLM）

Combating Murine Cytomegalovirus: A New Alliance in Antiviral Therapy

Cytomegalovirus (CMV) infections can pose significant health risks, particularly in immunocompromised individuals. This research explores the potential of combining antiviral immunotoxins with antiviral drugs, ganciclovir (GCV) or cidofovir (HPMPC), to combat murine cytomegalovirus (MCMV) infection. The study investigates the synergistic effects of this combination therapy, highlighting its potential for improving treatment outcomes.

A Powerful Alliance: Immunotoxins and Antiviral Drugs

This study demonstrates that combining antiviral immunotoxins with GCV or HPMPC leads to synergistic inhibition of MCMV yield in cell cultures. The research suggests that this combination therapy could be more effective than either treatment alone, potentially reducing the viral load and improving patient outcomes.

A New Oasis in Antiviral Therapy: Synergistic Approaches

This study underscores the importance of exploring synergistic treatment strategies for viral infections. By combining different antiviral agents, researchers can potentially achieve better outcomes and minimize the risk of drug resistance. This research provides valuable insights into the development of more effective antiviral therapies.

Dr.Camel's Conclusion

This study offers a compelling case for exploring combination therapies for viral infections. By combining antiviral immunotoxins with antiviral drugs, researchers can potentially achieve greater efficacy and improve the management of CMV infections.
Date :
  1. Date Completed 1997-03-14
  2. Date Revised 2019-09-20
Further Info :

Pubmed ID

8955511

DOI: Digital Object Identifier

10.1016/s0166-3542(95)00986-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.